Proleukin

Iovance raised the midpoint of its 2026 revenue outlook by $55 million after stronger Amtagvi and Proleukin demand, and the stock followed its 31.5% September 29 surge with another gain on September 30. The harder question is whether accelerating commercial adoption can now outrun cash burn and the risks inherent in scaling personalised cell therapy.